Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
Should you invest $1,000 in right now?
Before you consider , you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.
The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of August 16th 2021
Here’s why the Starpharma (ASX:SPL) share price is having such a stellar end to the week
4 ASX healthcare shares at 52-week lows
Here’s why the Starpharma (ASX:SPL) share price is tumbling 8% today
Starpharma (ASX:SPL) share price lifts on Omicron study results
Share Market News
Not enough: Starpharma (ASX:SPH) share price plunges despite 200% revenue growth
What is happening to the Starpharma (ASX:SPL) share price today?
Starpharma (ASX:SPL) share price shoots 6% higher on Roche agreement
Starpharma (ASX:SPL) share price climbs 3% on back of Vietnam launch
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
Starpharma Holdings Ltd is an Australia-based company engaged in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications. It focuses on the development of VivaGel for the management and prevention of bacterial vaginosis, and as a condom coating and VIRALEZE an antiviral nasal spray.
|13 May 2022||$0.78||$-0.02||-2.50%||227,100||$0.81||$0.82||$0.78|
|12 May 2022||$0.80||$0.01||1.27%||515,040||$0.78||$0.80||$0.76|
|11 May 2022||$0.79||$0.02||2.58%||239,197||$0.78||$0.79||$0.76|
|10 May 2022||$0.78||$0.02||2.63%||322,790||$0.73||$0.78||$0.73|
|09 May 2022||$0.76||$-0.05||-6.13%||452,182||$0.80||$0.80||$0.75|
|06 May 2022||$0.82||$0.00||0.00%||337,934||$0.79||$0.82||$0.78|
|05 May 2022||$0.81||$0.01||1.24%||104,667||$0.81||$0.83||$0.81|
|04 May 2022||$0.81||$-0.02||-2.41%||166,700||$0.83||$0.83||$0.80|
|03 May 2022||$0.83||$0.00||0.00%||125,623||$0.83||$0.83||$0.81|
|02 May 2022||$0.83||$-0.02||-2.35%||177,192||$0.84||$0.84||$0.82|
|29 Apr 2022||$0.85||$0.05||6.25%||323,722||$0.84||$0.86||$0.82|
|28 Apr 2022||$0.80||$-0.04||-4.76%||329,332||$0.84||$0.88||$0.80|
|27 Apr 2022||$0.84||$0.04||5.00%||98,376||$0.84||$0.84||$0.81|
|26 Apr 2022||$0.80||$-0.02||-2.42%||1,481,904||$0.82||$0.84||$0.79|
|22 Apr 2022||$0.83||$-0.02||-2.37%||408,007||$0.83||$0.84||$0.82|
|21 Apr 2022||$0.85||$0.01||1.19%||126,099||$0.84||$0.86||$0.84|
|20 Apr 2022||$0.84||$0.00||0.00%||252,163||$0.84||$0.85||$0.83|
|03 Dec 2021||Jacinth (Jackie) Fairley||Issued||493||$594,498|| |
Issue of securities. 5,502,890 - Performance Rights
|01 Oct 2021||Jacinth (Jackie) Fairley||Cancelled||224||$292,125|| |
Cancellation of securities. 5,009,530 - Performance Rights
|31 Aug 2021||Zita Peach||Buy||8||$10,042|| |
|30 Aug 2021||Jacinth (Jackie) Fairley||Buy||50||$57,979|| |
|27 Aug 2021||Robert Thomas||Buy||25||$28,990|| |
|Ms Zita Peach||Non-Executive Director||Oct 2011|| |
Ms Peach has more than 25 years of executive commercial experience in the pharmaceutical, biotechnology, medical devices and health services industries. She worked for CSL Limited and Merck Sharp & Dohme, the Australian subsidiary of Merck Inc. Ms Peach's most recent executive position was as the Managing Director for Australia and New Zealand and Executive Vice President, South Asia Pacific for Fresenius Kabi, provider of pharmaceutical products and medical devices to hospitals. Previously, Ms Peach was Vice President, Business Development, for CSL Limited, a position she held for ten years. Ms Peach has substantial international and local experience in the areas of pharmaceutical/medical device product development, commercialisation of products and technologies, marketing and sales, licensing, M&A and international expansions. She has overseen manufacturing, logistics, regulatory affairs, quality assurance, clinical services, human resources, finance, information technology, public policy, business development, marketing and sales at Managing Director and CEO level. Ms Peach is Chairman of Pacific Smiles Group Limited, and a Non-Executive Director of the ASX-listed Monash IVF Group Limited, and Visioneering Technologies, Inc. Ms Peach is also a member of the Hudson Institute of Medical Research Board. Currently, she is Director of Monash IVF Group Limited, Visioneering Technologies, Inc. and Pacific Smiles Group Limited. She is a member of Risk committee.
|Mr Robert Bain Thomas||Non-Executive DirectorNon-Executive Chairman||Dec 2013|| |
Mr Thomas has a background in financial services and capital markets and is a non-executive director of several Australian listed companies. Formerly Mr Thomas was a Partner of Potter Partners (now UBS) where he was also Head of Research. Mr Thomas is the former Chief Executive Officer (CEO) of County NatWest Securities and then became CEO and then Chairman of Citibank Corporate and Investment Bank in Australia. Mr Thomas has also held the position of Chairman at Australian Wealth Management Ltd (ultimately IOOF Ltd), TAL and HeartWare International Inc, the second largest global manufacturer of left ventricular assist heart pumps. Mr Thomas is currently a non-executive director of ASX listed Biotron Limited and Clarity Pharmaceuticals Limited. Mr Thomas is also Chair of AusBio Ltd, Grahger Retail Securities, Co-Chair of the State Library of NSW Foundation and a director of O'Connell Street Associates. He has experience in Mergers & Acquisition (M&A) and capital markets including advising on the floats of Commonwealth Bank of Australia and Qantas, and experience in Audit and Risk Management. Mr Thomas is also approved under the NSW prequalification scheme for Audit and Risk Committee Independent Chairs and Members for government/public sector agencies and has previously served as the Chairman of the Audit and Risk Committee of Virgin Australia Limited (for 11 years), HeartWare International Inc, REVA Medical Limited and the State Library of NSW. He is a member of Risk committee.
|Mr David McIntyre||Non-Executive Director||Mar 2020|| |
Mr McIntyre has more than 20 years of experience including 18 years in the life sciences sector, having held various C-suite level roles at Tessa Therapeutics, Inc., AVITA Therapeutics, Inc., HeartWare International, Inc., and Braeburn, Inc. Mr McIntyre's experience also includes seven years as a Partner at Apple Tree Partners, a venture capital and growth equity fund, giving him a deep knowledge of, and extensive contacts, in the US pharma, medical device and biotech markets. During this time, Mr McIntyre served as a nonexecutive director of several United States life science companies. Prior to entering life sciences, Mr McIntyre practiced as a senior attorney at Baker & McKenzie and KPMG in M&A, initial public offerings, and corporate law and also held various senior finance roles in both multi-national companies and small growth companies. Mr McIntyre has experience in the areas of accounting/corporate finance, audit and risk, strategy and risk management. He is chair of Risk committee.
|Dr Jacinth (Jackie) Kincaid Fairley||Chief Executive OfficerExecutive Director||Jul 2006|| |
Dr Fairley has more than 30 years of experience in the pharmaceutical and biotechnology industries working in senior management roles with companies including CSL Limited (CSL) and Faulding (now Pfizer). In those roles Dr Fairley had responsibilities which included clinical, regulatory, business development, product development management and general management. At Faulding Dr Fairley was responsible for Global Product Development, Regulatory Affairs and Business Development for Faulding's Hospital Business which operated in more than 60 countries Dr Fairley is a non-executive director of listed investment company Mirrabooka Investments Limited and Chairman of the Invest Victoria Advisory Board. Dr Fairley is a past member of the Federal Government's Commonwealth Science Council and Pharmaceutical Industry Working Group; the Federal Ministerial Biotechnology Advisory Council and previously served on the Board of Melbourne Business School for 10 years.
|Ms Lynda Cheng||Non-Executive Director||Aug 2021|| |
Ms Cheng has more than 25 years of experience as a finance executive including more than 15 years at Visy Industries/Pratt Holdings and 10 years in investment banking. Ms Cheng is currently Director of Corporate Development and Mergers & Acquisitions at Visy Industries / Pratt Holdings and has held various other roles in the group including CFO. She began her career as a lawyer at Blake Dawson, before moving into investment banking with J.P. Morgan in their Melbourne, Sydney, San Francisco and New York offices. Ms Cheng is currently a non-executive director of Export Finance Australia and a member of the Wesley College Council. Ms Cheng previously served as a member of the Australian Government's International Development Policy Expert Panel and Deputy Chair and Chair of the Finance, Audit and Risk Committee of South East Water. She will also appointed as member of Risk Committee of SPL effective 01/08/2021.
|Dr Jeff Davies||Non-Executive Director||Apr 2022|| |
Dr Davies is a former CSL executive, with over 35 years of biopharmaceutical experience, holding senior executive roles at CSL, including Executive Vice President & General Manager at CSL for the Asia-Pacific region, and Global Head of Plasma Product Research and Development at CSL-Behring, Switzerland. His experience spans R&D, business operations, drug development and product commercialisation.
|Mr Nigel Baade||Chief Financial OfficerCompany Secretary||Jan 2009|| |
|Nigel Baade||Chief Financial OfficerCompany Secretary|| |
|A Eglezos||VP Business Development|| |
|J R Paull||VP Development & Regulatory Affairs|| |
|D J Owen||VP Research|| |
|HSBC Custody Nominees (Australia) Limited||125,584,383||30.93%|
|JP Morgan Nominees Australia Pty Limited||49,079,638||12.00%|
|Citicorp Nominees Pty Limited||23,997,000||5.91%|
|National Nominees Limited||11,486,806||2.83%|
|BNP Paribas Noms Pty Ltd <Drp>||9,955,488||2.45%|
|T & N Argyrides Investments P/L <T & N Argyrides Pension A/C>||4,970,000||1.22%|
|BNP Paribas Nominees Pty Ltd Acf Clearstream||4,408,891||1.09%|
|Mirrabooka Investments Limited||4,067,044||1.00%|
|Applecross Secretarial Services Pty Ltd <L Gorr Family A/C>||3,361,550||0.83%|
|Ms Jacinth Fairley||3,252,386||0.80%|
|Mr Kingsley Bryan Bartholomew||3,054,025||0.75%|
|Mr Peter Murray Jackson||3,020,000||0.74%|
|BNP Paribas Nominees Pty Ltd <Agency Lending Drp A/C>||2,950,611||0.73%|
|BNP Paribas Nominees Pty Ltd <IN AU Noms Retail Client>||2,766,480||0.68%|
|HSBC Custody Nominees (Australia) Limited A/C 2||2,484,209||0.61%|
|Dollar Coin Investments Pty Ltd <Cousins Discretionary A/C>||1,990,030||0.49%|
|Peppertree Custodian Services Pty Ltd <Mulcahy Superannuation>||1,669,950||0.41%|
|Merrill Lynch (Australia) Nominees Pty Limited||1,540,474||0.38%|
|Commonwealth Scientific and Industrial Research Organisation||1,448,798||0.36%|
|Mr David Michael Hosey + Mrs Andrea Jane Hosey||1,429,422||0.35%|